|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>17</b>, a potent dual VEGFR3 and VEGFR2 inhibitor, effectively suppresses both lymphangiogenesis and angiogenesis in a 3D-microfluidic tumor lymphangiogenesis assay and in vivo corneal assay while SAR131675 blocks only lymphangiogenesis.
|
31513411 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was the evaluation of serum levels of osteopontin (OPN) and tumor endogenous angiogenic factors such as vascular-endothelial growth factor (VEGF), vascular-endothelial growth factor receptor 2 (VEGF R2), endostatin, angiostatin and thrombospondin 1, in prostate cancer (PC) patients.
|
30178447 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth.
|
30700502 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chitosan sulfate inhibits angiogenesis via blocking the VEGF/VEGFR2 pathway and suppresses tumor growth in vivo.
|
30694269 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aimed to investigate the potential systemic antitumor effects of stereotactic ablative radiotherapy (SABR) and apatinib (a novel vascular endothelial growth factor receptor 2 inhibitor) via reversing the immunosuppressive tumor microenvironment for lung carcinoma.
|
31476848 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Judicious dosing of antiangiogenic agents such as apatinib (VEGFR2-TKI) can modulate the tumor immunosuppressive microenvironment, which contributes to resistance to anti-PD-1/PD-L1 treatment.
|
30755403 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
They also suggest that anti-NHL activity of apatinib might be associated with inhibition of tumor cell growth and induction of apoptosis as well as anti-angiogenesis by targeting VEGFR2 and its downstream Ras/Raf/MEK/ERK pathway.
|
30423319 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a PC-3 xenograft mouse model, treatment with anti-VEGFR2-AF repressed tumor growth and angiogenesis as effectively and safely as US FDA-approved anti-VEGFR2 therapeutic, ramucirumab.
|
31578782 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When overexpressed in gastric cancer cells, VEGFR2 increased cellular proliferation and invasion in vitro and tumor formation in xenograft models.
|
30819137 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein levels of VEGF and VEGFR were mainly associated with the patient's age, tumor site, tumor size, tumor stage, and lymph node metastasis.
|
30862805 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among antiangiogenic therapies, targeting the vascular endothelial growth factor receptor 2 (VEGFR2) that is over-expressed on tumor vasculatures has been a promising strategy.
|
30724452 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
VEGF-A/VEGFR2 complex is the major signaling pathway involved in angiogenesis and the inhibition of this axis retards tumor growth and inflammatory disorders progression, reducing vessel sprouting.
|
31025286 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ISA-2011B-treatment reduced expression of pSer-473 AKT (p < 0.001) and its downstream effectors including cyclin D1, VEGF and its receptors, VEGFR1 and VEGFR2 (p < 0.001) in xenograft tumors.
|
30104711 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adjuvant, dual anti-angiogenic therapy targeting VEGFR2 and VEGFR3 significantly enhances tumour chemotherapeutic uptake compared to control.
|
29972342 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, TRPV4 deletion/knockdown enhanced VEGF-mediated migration in vitro and increased expression of VEGFR2 in vivo in the vasculature of TRPV4 KO tumors compared with wild-type tumors.
|
29957061 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry of stromal PDGF-C, PlGF, SD1-α, Tie-2, and VEGFR-2 showed statistical differences between tumors at the time of relapse and after the switched therapy.
|
30953637 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of VEGFR1 and VEGFR2 on tumor cells and immunosuppressive tumor-microenvironment were related to tumor growth in patients with chordomas.
|
31240525 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, emodin inhibited the tumor growth in xenograft model and the expressions of VEGFR2, PI3K and p-AKT in vivo.
|
31288005 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, the immuno-fluorescent staining results confirmed the expression pattern of VEGFR-2 among various PrCa tumors.
|
31598404 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although both conventional and low-dose anti-VEGFR2 antibody treatments normalize tumor vessels, low-dose VEGFR2 blockade results in more robust immune cell infiltration and activation and promotes the secretion of osteopontin (OPN) by CD8<sup>+</sup> T cells.
|
31848190 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of the VEGFR-2 blocks angiogenesis and attenuates tumor growth, but cancers may evade this effect through activation of the hepatocyte growth factor receptor MET.
|
31142504 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor tissue radioactivity of the anti-VEGFR2 targeted group at 24 and 72 h after intratumoral injection was significantly higher than that of the non-targeted groups (all P < 0.05).
|
30874973 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1.
|
31562188 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, STING-based immunotherapy was maximally effective when combined with VEGFR2 blockade and/or immune checkpoint blockade (αPD-1 or αCTLA-4), leading to complete regression of immunotherapy-resistant tumors.
|
31343989 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
No significant correlation was found between expression of VEGF<sub>165</sub>b and VEGFR2 in tumours and non-tumor surgical margins.
|
29926253 |
2019 |